ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure

Impact · against what's priced in

Positive clinical data for dapirolizumab pegol (DZP) in SLE provides a potential new growth driver for both UCB and Biogen. For Biogen, this adds a positive catalyst to a valuation that currently ignores most of its non-Alzheimer's pipeline growth.

BIIB+0.20

Not in the price yet

In context

While the current price focuses almost entirely on LEQEMBI and the MS decline, positive SLE data for DZP introduces a secondary growth driver that is not currently factored into the market's conservative valuation.